Crucell Presents Data From Rabies Antibody Cocktail Study

Dutch biotechnology company Crucell discussed results from an India-based Phase I study of its rabies monoclonal antibody cocktail. 

 

The randomized, double-blinded, placebo-controlled trial tested the cocktail alone against rabies and in combination with a rabies vaccine.

When the cocktail was given alone, virus-neutralizing activity could be seen at both dose levels administered. When the cocktail was administered in combination with a vaccine, all volunteers seroconverted within 14 days upon the initiation of treatment, Crucell said.

Data from the study confirm results of a Phase I trial conducted in the U.S. The company expects to start Phase II studies in the first half of 2008 in the U.S. and the Philippines.